Our Head of R&D Cell Culture Systems, Ulla Schultz, recently joined a panel discussion focusing on the challenges faced by cell therapy manufacturers in the development of allogeneic CAR-T.

What will you learn?

  • How to overcome the challenges in developing an allogeneic therapy
  • The advantages and disadvantages of an allogeneic product
  • How to best manufacture your T-cell products
  • The future of allogeneic CAR-T and similar products

The experts in this roundtable are:

  • Marcos Langtry, head of Allogeneic Cell Therapy, Lonza Pharma & Biotech
  • Paul Maciocia, Research Department of Heamatology and Cancer Institute, UCL
  • Ulla Schultz, Head of R&D Cell Culture Systems, CellGenix

You can watch the panel discussion here.